Since STING agonists are being pursued clinically as anti-cancer immunotherapeutics (45), we evaluated the response of a relevant population of patients with locally advanced or borderline resectable pancreatic cancer (46). This evidence concerns the gene STING1 and pancreatic neoplasm.